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Findings
• The majority of patients were taking an analgesic, PPI and 
a lipid-lowering agent at baseline.
• Sixty eight percent of patients (n=13) were identified as 
taking at least one medication that is considered 
potentially inappropriate by STOPPFrail criteria. 
• Clinical pharmacist was able to identify not only 
medications for discontinuation but also medications for  
optimization, which included adjusting the dose and 
switching to a more suitable therapy alternative based on 
safety or efficacy. 
• While multiple methods of gathering data were used, the 
most utilized method was telephone interviews (n=13), 
followed by telehealth (n=4) and consult (n=2). 
• A very small proportion of pharmacist recommendations 
were accepted by the provider.
• The average time spent on chart review was 1.5 hours.
Study Limitations
• Non-randomized trial with a small sample size and lack of 
control group for comparison
• Short duration of follow-up to track provider rejection or 
acceptance of recommendations and safety outcomes 
• Scheduled patient visits may be cancelled, postponed or 
missed unexpectedly, which affected opportunities for 
intervention.
• Because the pharmacist is not formally integrated into the 
palliative care team, there was an educational component 
to patients and providers about the pharmacist’s role.
• Changes to the pharmacist process (i.e. telehealth, 
telephone and consult) were made throughout the study. 
This may have led to inconsistent results as one method 
may have been more effective than another. 
• A large barrier to utilizing telehealth was the lack of 
standardization of technology. 
• The palliative care consult service makes 
recommendations to providers and does not change active 
medication orders. Since recommendations are written as 
progress notes and may be either faxed or sent through 
EMR message, there is limited certainty if the provider 
received the recommendations in a timely manner.
• Many patients had various specialists managing their care, 
which complicated sending recommendations to the most 
appropriate provider. 
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• Pharmacist involvement in outpatient palliative care may be 
valuable as evidenced by the number of interventions 
identified by the clinical pharmacist. 
• Many patients were taking medications, such as lipid-
lowering agents and PPIs, that may not be consistent with 
their goals of care based on the STOPPFrail criteria and may 
be subject to deprescribing. 
• However, many barriers to providing meaningful 
interventions were identified in this study. 
• While telehealth potentially provided convenience to the 
patient and caregivers, utilization by home health nurses 
was limited due to lack of standardization of technology.
• Telephone interviews made by the clinical pharmacist 
allowed proper medication reconciliation prior to the 
palliative care visit, but non-medication related issues, 
including hospice referrals, may be prioritized after the visit 
by the NP and the provider. 
• Pharmacy consult requested by palliative care nurse 
practitioners allowed targeted efficiency, but it did not 
allow formal pharmacist integration in the outpatient 
palliative care team. 
• Further studies quantifying the pharmacist’s role in 
outpatient palliative care are warranted. 
Study Design
• The primary objective is to evaluate the clinical 
pharmacist’s role within an outpatient palliative care 
team performing medication reconciliation and review 
and to potentially streamline the work involved in the 
palliative care consult service. Medication review 
includes de-prescribing high-risk medications and 
optimizing medications in symptom management for 
palliative care patients.
Methods 
Health & Services
• The goals of palliative care are often different from the 
traditional goals of medicine. Patients with limited life 
expectancy unnecessarily have a large medication 
burden, which may increase the risk of adverse drug 
events due to side effects or drug-drug interactions.
• Several studies emphasize the need for medication de-
prescribing in a variety of palliative care populations. 
• Fahlman et al identified 44% of community dwelling 
elderly in their last year of life received at least one 
inappropriate medication based on the Beers criteria.1
• Holmes et al developed a census that rated the 
appropriateness of medications of 34 patients with 
advanced dementia. Results showed that 29% of 
patients were prescribed medication considered never 
appropriate and 21% of patients were prescribed a 
medication considered rarely appropriate.2
• Current studies demonstrating the integration of 
pharmacists in the palliative care setting are limited. 
• Whitman et al assessed pharmacists de-prescribing 
interventions in older adults with cancer using three 
geriatric screening tools (Beers Criteria, STOPP and MAI). 
Results showed the pharmacists were able to identify 
and de-prescribe 73% of potentially inappropriate 
medications, with an average of 3 medications de-
prescribed per patient.3
• The evaluation of the clinical pharmacist and their 
interventions may allow better care for palliative care 
patients and improve interdisciplinary care within the 
palliative care setting.
• The study utilizes the STOPPFrail and Beers criteria as a 
guide for de-prescribing potentially inappropriate 
medication, optimizing medication use or adding 
medication for symptom management. However, this 
does not exempt clinical decision making that relies on 
other patient factors. 
• Study Period
• January 2020 to February 2020
• Study was followed up until March 2020
• Primary Endpoints 
• Number of medications discontinued
• Number of recommendations accepted by 
provider
• Number of medications recommended for 
symptom management
• Time spent on chart/medication review
• Inclusion criteria
• Adults at least 55 years of age
• Enrolled in outpatient palliative care service
• Have at least 5 routine medications at the time 
of consult 
Results 
Telehealth Telephone
Consult
• A telehealth visit is a video 
consult conducted through 
Zoom platform and is initiated 
by the home health RN
• Nurse practitioners (NPs) 
screen patients for study 
eligibility as patients are 
scheduled for outpatient 
palliative care visits  via 
telehealth
• Clinical pharmacist reviews 
chart prior to the visit and 
identifies potentially 
inappropriate medications and 
optimizing medication 
regimen
• Make recommendations to NP 
via a 3-way telehealth call with 
home health RN and NP
• NP passes on final 
recommendations to the PCP
• Clinical pharmacist screens 
patients for study eligibility
• Prior to the scheduled home 
visit with NP, pharmacist 
initiates the interview to the 
patient via telephone or 
requests a medication 
administration record (MAR) 
to review current 
medications
• Pharmacist sends 
recommendations to NP at 
least 2 days prior to the visit
• After the visit and in 
consultation with NP, 
pharmacist sends 
recommendations to the 
PCP
• NPs initiate and request 
pharmacy consult on specific 
patients to review current 
medications and provide 
assessment 
• Pharmacist reviews chart 
and/or interviews patient and 
provides recommendations to 
NP 
• NP either accepts or denies 
recommendations and sends 
to PCP
Demographics, N=19
Age, years, mean (range) 81 (63-95)
Sex, female, No. (%) 11 (58%)
Number of medications, average (range)
Total 15 (5-23)
Scheduled 11 (4-17)
PRN 3 (0-10)
Number of patients taking, No. (%)
Analgesic 15 (79%)
Opioid 4 (21%)
Non-opioid 11 (58%)
Long-term antibiotic 2 (11%)
Steroid 2 (11%)
Proton pump inhibitor (PPI) 11 (58%)
Lipid-lowering agent 11 (58%)
Ezetimibe 2 (11%)
Statin 9 (47%)
Anticoagulant 6 (32%)
Anticholinergics 3 (16%)
Aspirin 5 (26%)
Reason for Palliative Care Consult, No. (%)
Dementia 4 (21%)
Heart failure 4 (21%)
Baseline Characteristics
Recommendations Accepted (n=6)
Medications Discontinued 3
PPI 1
Supplement 2
Medication Optimized 3
Recommend antibiotic 1
Administration 1 
Dose adjustment 1
45%
47%
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Medication Discontinuation
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Medication
Discontinuation
Medication
Optimization
Symptom
Management
Number of recommendations 29 30 5
Recommendations Identified (n=64)
Medication Discontinuation, No. 
PPI 8
Lipid-lowering agent 2
Anti-hypertensives 4
Antiplatelets 2
NSAIDs 2
Urogenital agents 1
CNS agents 2
Memantine 1
Supplements 5
Antibiotic 2
Medication optimization, No. 
Therapy alternative 9
Dose adjustment 15
Administration 2
Therapy addition 4
Symptom management, No.
Pain 3
Bowel Regimen 1
Appetite stimulant 1
Recommendations Identified (n=64)
